Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07739667

Blood Pressure Measurement Using Vitacam

The purpose of this clinical investigation is to collect data for the development, testing, and validation of a blood pressure measurement algorithm for a contactless vital signs monitor, Vitacam, according to the ISO 80601-2:2019 standard for validating non-invasive sphygmomanometer, with the intention of disseminating the validation results through a peer-reviewed scientific publication.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Tampere University

Tampere, Finland

Location status: Recruiting

Location contact

Anna Karhu, MSc

SUB_INVESTIGATOR

About this study

Vitacam is a Software-as-Medical Device (SaMD) for measuring vital physiological parameters from a video sequence from a face and chest, which uses computer vision techniques and remote photoplethysmography. This study concerns the development and validation of blood pressure measurements using Vitacam according to internationally recognised ISO (the International Organization for Standardization) standards with modifications imposed by cuffless measurements.

Based on these standards, measurements are collected simultaneously using Vitacam from facial videos, and a clinically validated auscultatory sphygmomanometer.

A minimum of 85 subjects are required for an EN ISO 81060-2:2019 + A2:2024 validation study with at least ≥30% of either sex. The SBP readings must be distributed such that ≥ 5% are ≤100 mmHG; ≥ 5% must be ≥ 160 and ≥ 20% is ≥ 140. The DBP readings must be distributed such that ≥ 5% are ≤60 mmHG; ≥ 5% must be ≥ 100 and ≥ 20% is ≥ 85. There must be at least 255 valid paired BP values.

The mean BP difference must be 5 mm/hg or less, and its standard deviations 8 mm/hg or less (criterion 1, section 5.2.4.2, EN ISO 80601-2:2019).

The standard deviation must also not exceed the value specified in Criterion 2 of the ISO standard, related to the mean difference to the reference BP.

Finally, a measuring device is considered acceptable if its estimated probability of a tolerable error (≤10mmHg) is at least 85%.

Vitacam is not intended for use in children and during pregnancy, so such subjects are excluded from the recruitment. It is intended to be used by elderly persons, so such subjects, able to give informed consent, will be recruited. As there is an increased prevalence of heart disease in the elderly, subjects diagnosed with atrial fibrillation or other irregular heart rhythms are neither excluded from the recruitment nor considered a special study population.

This study is a cross-sectional, observational, multi-site study conducted in co-operation with the University of Tampere.

This study will not affect any treatment or care, to any study subjects and it shall not have any impact on the duties of the clinical staff at the places of data gathering.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age 18 years or older
  • Ability to give informed consent
  • Volunteering for the study
  • Fluent Finnish or English

Exclusion criteria

  • Age under 18 years
  • Pregnancy
  • Inability to give informed consent
  • Denial

Treatment and study plan

rPPG blood pressure measurement medical device software

Device

The investigational blood pressure measuring device uses remote photoplethysmography from video and does not use an inflatable arm cuff.

Primary outcomes

  1. SBP criterion 1: Mean difference and standard deviation between cuffless device systolic blood pressure and reference blood pressure measurement.

    Time frame: A period of 5-15 minutes during which the blood pressure of the participant is measured 3-8 times using a clinically validated auscultatory sphygmomanometer, while videos are recorded.

    The mean BP difference must be 5 mm/hg or less, and its standard deviations 8 mm/hg or less (criterion 1, section 5.2.4.2, EN ISO 80601-2:2019).

  2. DBP criterion 1: Mean difference and standard deviation between cuffless device diastolic blood pressure and reference blood pressure measurement.

    Time frame: A period of 5-15 minutes during which the blood pressure of the participant is measured 3-8 times using a clinically validated auscultatory sphygmomanometer, while videos are recorded

    The mean BP difference must be 5 mm/hg or less, and its standard deviations 8 mm/hg or less (criterion 1, section 5.2.4.2, EN ISO 80601-2:2019).

Secondary outcomes

  1. Criterion 2: Inter-subject variability of device-reference blood pressure differences

    Time frame: A period of 5-15 minutes during which the blood pressure of the participant is measured 3-8 times using a clinically validated auscultatory sphygmomanometer, while videos are recorded.

    The standard deviation of participant-level mean differences between cuffless device blood pressure measurements and reference blood pressure measurements is in accordance with table 1 of 5.2.4.1.2 (b) from ISO 81060-2:2019+A2:2024

Study contacts

Contact information is provided by the study sponsor or research team.

Moyeen Ahmad

CONTACT

[email protected]

+35850486879

Sponsors and collaborators

Lead sponsor

Evondos Oy

Industry

Collaborators

  • Tampere University

Registry information

Important dates

Study start
2026
Primary completion
2026
Study completion
2027
First posted
Jul 31, 2026
Registry last updated
Jul 31, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.